CD59, 16.3A5, 1F5, 1F5 antigen, CD59 glycoprotein, EL32, EJ16, G344, HRF-20, MAC-IP, MACIF, Ly-6-like protein, MEM43, MIRL, MEM43 antigen, MIN2, MIN3, MSK21, p18-20, Protectin, MAC-inhibitory protein, MIC11, T cell-activating protein, CD59 antigen, EJ30, HRF20, Human leukocyte antigen MIC11, Lymphocytic antigen CD59/MEM43, MIN1
(tested or 100% immunogen sequence identity)
Also available Azide-free
CD59 antibody was raised against recombinant Full-length Human Protein.
Reacts with human CD59, a 20kDa glycosyl phosphatidyl-inositol (GPI)-anchored cell surface protein. CD59 regulates complement-mediated cell lysis, and it is involved in lymphocyte signal transduction. This protein is a potent inhibitor of the complement membrane attack complex, whereby it binds complement C8 and/or C9 during the assembly of this complex, thereby inhibiting the incorporation of multiple copies of C9 into the complex, which is necessary for osmolytic pore formation. CD59 is widely distributed on cells in all tissues. It inhibits formation of MAC, thus protecting cells from complement-mediated lysis. The expression of CD59 on erythrocytes is important for their survival. Genetic defects in GPI-anchor attachment, that cause a reduction or loss of CD59 and CD55 on erythrocytes produce the symptoms of the disease paroxysmal hemoglobinuria (PNH). It is useful for study on GPI-anchored proteins, PNH and CD59 functions. Optimal dilution of the CD59 antibody should be determined by the researcher. Staining of formalin-fixed tissues requires boiling tissue sections in 10mM Citrate buffer, pH 6.0, for 10-20 min followed by cooling at RT for 20 min.
0.01% BSA, 0.05% sodium azide